

Provider Communications

Massachusetts



Date: Dec. 19, 2025

To: All WellSense Providers

From: WellSense Health Plan

Subject: **Pharmacy benefit updates**

Product: ☒ MassHealth ☐ MA Clarity plans ☐ Senior Care Options

Pharmacy benefit updates

MassHealth evaluates drug coverage on an ongoing basis and updates [its drug list](#) accordingly. As a result of updates to MassHealth's drug list, we're making the following pharmacy updates to GLP-1 agents effective Feb. 17, 2026. MassHealth will add any additional information about these changes to the list on the effective date.

Updated policies

The following clinical policies have been updated, effective Feb. 17, 2026:

- Antidiabetic Agents - Non-Insulin and Combination Products
 - A step-through metformin has been added for GLP-1 agents for treatment of prediabetes.
 - The recertification criteria for GLP-1 agents for diabetes or prediabetes has been updated to look for documentation of meeting A1c treatment goals, reduction in A1c or a treatment plan.
 - Only Mounjaro and Ozempic will be covered for off-label treatment of obesity.
 - Byetta has been removed from BOGL and guideline given the brand product has been discontinued by the manufacturer and is obsolete.
- Anti-Obesity Agents
 - Step-through phentermine and Mounjaro have been removed for Zepbound.
 - Wegovy will be covered for treatment of obesity in adults [using the same criteria](#) as Zepbound.

Provider Communications

Massachusetts



- Criteria for Wegovy has been updated for diagnosis of NASH/MASH to remove requirement of trial with Ozempic 2 mg for members with comorbid condition of T2DM or prediabetes and require a step-through semaglutide for Saxenda for treatment of obesity in pediatric members.

Questions?

Please reach out Provider Service at 888-566-0008 or provider.info@wellsense.org with any questions. For secure communication, please register or login to the [provider portal](#).